InVivo Therapeutics (NSDQ:NVIV) said today that the FDA cleared an expansion of its Inspire study of its neuro-spinal scaffold, now set to enroll up to 20 patients, and announced the 9th and 10th implantation in the trial, though the 10th patient died of an unrelated stroke. The Cambridge, Mass.-based company’s neuro-spinal scaffold is surgically implanted following acute spinal […]
InVivo Therapeutics
InVivo Therapeutics touts case study in 1st spine scaffold implant
InVivo Therapeutics (NSDQ:NVIV) this week touted a case study of the 1st implantation of its spinal scaffold, a bioresorbable device designed to help treat traumatic spinal cord injuries. The study, published in Neurosurgery, the journal of the Congress of Neurological Surgeons, involved a 25-year-old man with an American Spinal Injury Assn. Grade A spinal cord injury sustained in a […]
NuVasive co-founder McKinley is Vascular Dynamics new COO | Personnel Moves June 9, 2016
NuVasive co-founder McKinley is Vascular Dynamics new COO Vascular Dynamics said it tapped NuVasive Inc. (NSDQ:NUVA) co-founder and former CEO James McKinley as its new chief operating officer. McKinley has held leadership positions at Advent Medical, Endosphere, Farallon Medical and Nellix, as well as NuVasive. “It is a tremendous opportunity to add Jim to our management team. […]
InVivo adds 20th clinical site to Inspire study
InVivo Therapeutics (NSDQ:NVIV) said today it added Philadelphia’s Hospital of the University of Pennsylvania as a site in the Inspire study of its neuro-spinal scaffold, bringing the total number of sites up to 20. The Cambridge, Mass.-based company’s neuro-spinal scaffold is surgically implanted following acute spinal cord injuries to act as a physical substrate for nerve […]
SonaCare inks marketing deal with Philips’ Invivo biz for its UroNav software
SonaCare Medical said today it inked a marketing alliance deal with Royal Philips (NYSE:PHG) business Invivo to license its UroNav fusion software with its Sonablate planning system. The new deal will allow clinicians to use the UroNav device to annotate and biopsy targeted prostate tissue and localize the tissue appropriate for ablation directly with its […]
Fourth patient converts from complete to incomplete spinal cord injury in InVivo trial
InVivo Therapeutics (NSDQ:NVIV) said today 4th patient in the Inspire study of its Neuro-Spinal Scaffold has improved from a complete AIS A spinal cord injury to an incomplete AIS B spinal cord injury. The Cambridge, Mass.-based company’s neuro-spinal scaffold is surgically implanted following acute spinal cord injuries to act as a physical substrate for nerve sprouting. […]
Patient enrolled in InVivo Therapeutics trial succumbs to injuries
InVivo Therapeutics (NSDQ:NVIV) said today that the 8th patient enrolled in a clinical trial of its spinal scaffold succumbed to his injuries nearly 5 days after a severe car accident. The death appears to be unrelated to InVivo’s bioresorbable neuro-spinal scaffold, which is designed to help heal traumatic spinal cord injuries. The patient was implanted April 12 with […]
InVivo adds 19th site at University of Virginia site to Inspire study
InVivo Therapeutics (NSDQ:NVIV) is continuing to add sites to the Inspire study of its NeuroSpinal Scaffold, announcing today that it added a new site at the Charlottesville’s University of Virginia Health System. The Cambridge, Mass.-based company’s neuro-spinal scaffold is surgically implanted following acute spinal cord injuries to act as a physical substrate for nerve sprouting. “Spinal […]
InVivo raises $32m, enrolls 7th patient in Inspire study
InVivo Therapeutics (NSDQ:NVIV) said today that it cleared $32.2 million from a stock offering after an over-allotment added another 560,000 shares, and said yesterday it enrolled a 7th patient in its Inspire study. Cambridge, Mass.-based InVivo floated 3.7 million units at $7.50 per unit in the initial offering, which closed March 18, bringing in $28 million. Each unit consists […]
InVivo prices $28m offering, shares slide
InVivo Therapeutics (NSDQ:NVIV) shares plunged today after the company priced a $28 million offering it plans to use to fund the Inspire clinical trial of its neuro-spinal scaffold. Each unit of the $7.50-per-share offering consists of a share of common stock and half of a 5-year warrant with an exercise price of $10, Cambridge, Mass.-based InVivo said. […]
InVivo continues Inspire study expansion, adds Thomas Jefferson Univ. Hospital
InVivo Therapeutics (NSDQ:NVIV) shows no signs of stopping the momentum in its Inspire trial, announcing today that it added Philadelphia’s Thomas Jefferson University Hospital as a clinical site for the Inspire study of its neuro-spinal scaffold, designed to treat patients with complete thoracic AIS A spinal cord injuries. The Cambridge, Mass.-based company’s neuro-spinal scaffold is surgically […]